白血病通过向新抗原特异性CD4+ T细胞施加1型调节程序来逃避免疫
该研究利用临床B细胞急性淋巴细胞白血病(ALL)样本和新小鼠模型,发现白血病微环境诱导新抗原特异性CD4+ T细胞获得1型调节(Tr1)功能,Tr1细胞抑制细胞毒性CD8+ T细胞,阻止有效清除白血病。在小鼠模型中,细胞毒药物联合抗PD-L1阻断可清除可测量残留病,并伴随新抗原特异性CD4+ T细胞从Tr1向Th1极化。
要点
- 白血病微环境诱导新抗原特异性CD4+ T细胞获得Tr1功能,进而抑制细胞毒性CD8+ T细胞。
- 白血病细胞通过模拟造血干细胞诱导Tr1细胞,使其从防癌角色转向促进临床复发。
- 小鼠模型中细胞毒药物联合抗PD-L1阻断可清除可测量残留病,并伴CD4+ T细胞向Th1极化。
核心结论
- 白血病通过模拟造血干细胞诱导新抗原特异性CD4+ T细胞获得Tr1功能,从而逃避免疫监视并促进复发。
- 治疗性将新抗原特异性CD4+ T细胞从Tr1向Th1极化,可能通过重塑免疫微环境改善免疫治疗。
研究设计与样本
- 研究使用临床B细胞急性淋巴细胞白血病(ALL)样本和新小鼠模型。
主要发现
- 新抗原特异性CD4+ T细胞在白血病微环境中被诱导获得1型调节(Tr1)功能,Tr1细胞抑制细胞毒性CD8+ T细胞,阻止有效清除白血病。
- 白血病细胞通过模拟造血干细胞诱导Tr1细胞,使其从防癌角色转向促进临床复发。
- 小鼠模型中,在细胞毒治疗基础上加用白细胞介素-10受体(IL-10R)阻断对Tr1发育影响有限,不足以改善白血病控制。
- 小鼠模型中,细胞毒药物联合抗PD-L1阻断清除了可测量残留病,并伴随新抗原特异性CD4+ T细胞从Tr1向辅助性T细胞1(Th1)状态极化。
关键数值与推荐
- 小鼠模型中,细胞毒药物联合抗PD-L1阻断清除了可测量残留病。
- 小鼠模型中,在细胞毒治疗基础上加用IL-10R阻断对Tr1发育影响有限,不足以改善白血病控制。
临床怎么用
- 作者认为,治疗性将新抗原特异性CD4+ T细胞从Tr1向Th1状态极化,可能通过重塑免疫微环境改善当代免疫治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The significance of endogenous immune surveillance in acute lymphoblastic leukemia (ALL) remains controversial. Using clinical B-cell ALL samples and a novel mouse model, we show that neoantigen-specific CD4+ T cells are induced to adopt type 1 regulatory (Tr1) function in the leukemia microenvironment. Tr1 cells then inhibit cytotoxic CD8+ T cells, preventing effective leukemia clearance. Leukemic cells induce Tr1 cells by phenocopying hematopoietic stem cells, which normally are subject to effective surveillance by this CD4+ subset. This mechanism effectively redirects Tr1 cells from a role in preventing cancer to maladaptively promoting clinical relapse. In mouse models, addition of interleukin-10 receptor (IL-10R) blockade to cytotoxic therapy modestly affected Tr1 development but was insufficient to improve leukemia control. In contrast, combined therapy with a cytotoxic agent and anti-PDL1 blockade eradicated measurable residual disease. This correlates with polarization of the neoantigen-specific CD4+ T-cell population from Tr1 toward T helper 1 (Th1) states. Our findings uncover a mechanism that enables leukemic relapse and resolves existing controversies on the role of immune surveillance toward this cancer type. Therapeutic polarization of neoantigen-specific CD4+ T cells away from Tr1 and toward Th1 states may improve contemporary immune therapies by reshaping the immune microenvironment toward states permissive for cytotoxic attack of residual leukemia.
引用
- Venkatesh H, Granados Centeno E, Luo Q, et al. Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells. Blood. 2025. PMID: 40906918. doi:10.1182/blood.2024028194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。